Results 51 to 60 of about 54,904 (251)

Novel CAR-T Cells Specifically Targeting Nectin4 Exhibit Effective Anti-Tumor Efficacy in Bladder Cancer Cell Lines

open access: yesBIO Integration
Background: Bladder cancer (BLCA) is one of the most common malignancies and the second most frequent urogenital tract tumor. Cell and gene therapy, which offer many advantages in treating BLCA, are urgently needed.
Jinping Niu   +7 more
doaj   +1 more source

A Rationally Designed Bovine IgA Fc Scaffold Enhances in planta Accumulation of a VHH-Fc Fusion Without Compromising Binding to Enterohemorrhagic E. coli

open access: yesFrontiers in Plant Science, 2021
We previously isolated a single domain antibody (VHH) that binds Enterohemorrhagic Escherichia coli (EHEC) with the end-goal being the enteromucosal passive immunization of cattle herds. To improve the yield of a chimeric fusion of the VHH with an IgA Fc,
Adam Chin-Fatt   +4 more
doaj   +1 more source

Anti-idiotypic VHH mediated environmentally friendly immunoassay for citrinin without mycotoxin

open access: yesFood and Agricultural Immunology, 2020
Competitive enzyme-linked immunosorbent assay (ELISA) is the most widely used method for rapidly screening of mycotoxins in contaminated food products; however, it involves the use of toxin-protein conjugates as a competitive antigen and toxin standards ...
Liang Xiong   +6 more
doaj   +1 more source

Protective effect of different anti-rabies virus VHH constructs against rabies disease in mice. [PDF]

open access: yesPLoS ONE, 2014
Rabies virus causes lethal brain infection in about 61000 people per year. Each year, tens of thousands of people receive anti-rabies prophylaxis with plasma-derived immunoglobulins and vaccine soon after exposure. Anti-rabies immunoglobulins are however
Sanne Terryn   +13 more
doaj   +1 more source

Multivalent Protein Nanorings for Broad and Potent SARS‐CoV‐2 Neutralization

open access: yesAdvanced Healthcare Materials, EarlyView.
A protein‐only, modular multivalent nanoscaffold displaying 20 anchor points, decorated with two different binders (10 of each), targeting the SARS‐CoV‐2 receptor‐binding domain is presented. The construct self‐assembles into stable, biocompatible, homogeneous nanoparticles, exhibit synergistic binding with fM IC50 values. It also detects spike at 9 ng 
Molood Behbahanipour   +11 more
wiley   +1 more source

Anticuerpos de cadena única de alpaca para la detección de antígenos de Fasciola hepatica

open access: yesRevista Peruana de Medicina Experimental y Salud Pública, 2018
Objetivo. Producir anticuerpos recombinantes de cadena única de alpaca que se unan con alta afinidad y especificidad al antígeno excretado-secretado (ES) de Fasciola hepatica para el desarrollo de tecnologías nuevas de diagnóstico de fascioliasis humana ...
Teresa Barreto   +6 more
doaj   +1 more source

Biocompatible Ink Optimization Enables Functional Volumetric Bioprinting With Xolography

open access: yesAdvanced Materials, EarlyView.
Xolography's reliance on weak‐base co‐initiators introduces unique biochemical constraints. By dissecting the effects of extracellular pH, osmolality, and lysosomotropic stress, this study defines the biochemical design space that enables fully biocompatible, cell‐laden volumetric printing. Abstract Xolography is a novel linear volumetric manufacturing
Erik Brauer   +17 more
wiley   +1 more source

Post-exposure Treatment with Anti-rabies VHH and Vaccine Significantly Improves Protection of Mice from Lethal Rabies Infection. [PDF]

open access: yesPLoS Neglected Tropical Diseases, 2016
Post-exposure prophylaxis (PEP) against rabies infection consists of a combination of passive immunisation with plasma-derived human or equine immune globulins and active immunisation with vaccine delivered shortly after exposure.
Sanne Terryn   +4 more
doaj   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

Home - About - Disclaimer - Privacy